<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02667470</url>
  </required_header>
  <id_info>
    <org_study_id>ATH-002</org_study_id>
    <nct_id>NCT02667470</nct_id>
  </id_info>
  <brief_title>Reproducibility Study of OABSS and Its Response to Treatment</brief_title>
  <acronym>RESORT part 2</acronym>
  <official_title>Overactive Bladder Symptom Scores (OABSS) Responsiveness Before and After Anticholinergic Treatment in Women With Overactive Bladder (OAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate change of Overactive Bladder (OAB) Symptom Score
      (OABSS) scores between before and after Solifenacin treatment to OAB patients and to evaluate
      correlation between change of OABSS scores and other measures for OAB symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in OABSS scores from prior to treatment and after treatment</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of change between OABSS scores and number of micturitions per day</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change between OABSS scores and number of incontinence episodes per day</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change between OABSS scores and number of urgency episodes per day</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change between OABSS scores and number of nocturia episodes per day</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change between OABSS scores and number of total voided volume per day</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change between OABSS scores and number of pads per day</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change between OABSS scores and total International Prostate Symptom Score (IPSS) score</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change between OABSS scores and IPSS Quality of Life (QoL) score</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change between OABSS scores and Patient Perception of Bladder Condition (PPBC) total score</measure>
    <time_frame>Prior to treatment and after treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>Oral</description>
    <arm_group_label>Solifenacin</arm_group_label>
    <other_name>Vesicare</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At screening visit (Week -2):

               -  Symptoms of OAB ≥ 3 months

               -  Number of urgency episodes in last 3 days ≥ 3

          -  Based on the 3-day micturition diary prior to Visit 1 (Week 0):

               -  Number of micturition per day ≥ 8

               -  Number of urgency episodes in 3 days ≥ 3

        Exclusion Criteria:

          -  At screening visit (Week -2):

               -  Stress is the predominant factor as determined by the investigator

               -  Indwelling catheters or practicing intermittent self-catheterization

               -  Symptomatic urinary tract infection, chronic inflammation

               -  Treatment for OAB was started, quitted or changed in 4 weeks

               -  Diabetic neuropathy

          -  At Visit 1 (Week 0):

               -  Patient who did not complete the 3-day micturition diary according to the
                  instruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: 1</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solifenacin</keyword>
  <keyword>Overactive bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

